Medtronic Inc.

According to Piper Jaffray, Medtronic (NYSE: MDT) Overweight rating is maintained. Piper Jaffray said that Medtronic reported Q4:F11 results with revenue of $4.295B (+2%) vs consensus of $4.290B. “EPS totaled $0.90 compared to expectations for $0.93. ICDs and spine were again weak, offset by...

According to Wunderlich Securities, Medtronic (NYSE: MDT) coverage is initiated with a Buy rating. Wunderlich Securities reported that it is initiating coverage of Medtronic, Inc. (MDT) with a Buy rating and a $46 target. “MDT remains the world's largest pure-play medical device company, with...

Oppenheimer surveyed 50 non-profit CEOs and CFOs to evaluate capital spending and pricing and volume trends as they relate to major medical device markets. In the report, Oppenheimer writes, “As we saw in our 2Q-4Q10 surveys, our respondents' hospitals continue to see a gradually healing capital...

According to Piper Jaffray, Medtronic's (NYSE: MDT) Resolute results show solid efficacy in a pivotal study. Piper Jaffray reported that results from Medtronic's U.S. pivotal trial evaluating the safety and efficacy of the Resolute drug eluting stent were presented this morning at the American...

According to Morgan Stanley, Medtronic (NYSE: MDT) endeavor potential is underappreciated. Morgan Stanley reported that RESOLUTE US data showed encouraging efficacy results and a very low rate of stent thrombosis that directly addressed safety concerns on prior data. “The study was non-randomized...

According to Oppenheimer, Medtronic (NYSE: MDT) continued to add to its list of near-term pipeline launches with late Friday's FDA approval of InterStim TherapyBowel Control. Oppenheimer reported that the fecal incontinence indication has been a solid driver of InterStim sales in the EU. “The US...

J.P. Morgan is lowering its FY12 estimate on Medtronic Inc. (NYSE: MDT). “Following the closing of the Ardian acquisition, we are lowering our FY12 EPS estimate another $0.03 to $3.53 (+4.4%),” J.P. Morgan writes. “This now puts us $0.13 below Street consensus ($3.66). On its own, Ardian is $0.05-....

The Associated Press reported on Friday that a panel at the Food and Drug Administration approved a brain stimulator made by Medtronic Inc. (NYSE: MDT) for the treatment of epilepsy. The panel voted 7 to 5 in favor of the approval and said that Medtronic must conduct follow-up studies of the brain...